Last reviewed · How we verify
intraocular injections of bevacizumab
intraocular injections of bevacizumab is a Small molecule drug developed by Samsung Medical Center. It is currently in Phase 2 development. Also known as: glaucoma filtering surgery.
At a glance
| Generic name | intraocular injections of bevacizumab |
|---|---|
| Also known as | glaucoma filtering surgery |
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT (NA)
- Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia (PHASE3)
- Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome (PHASE2, PHASE3)
- Intravitreal Bevacizumab for Inflammatory Neovascular Membranes (PHASE3)
- Use of Bevacizumab in Trabeculectomy Surgery (PHASE4)
- Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration (NA)
- VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP (PHASE4)
- Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intraocular injections of bevacizumab CI brief — competitive landscape report
- intraocular injections of bevacizumab updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI
Frequently asked questions about intraocular injections of bevacizumab
What is intraocular injections of bevacizumab?
intraocular injections of bevacizumab is a Small molecule drug developed by Samsung Medical Center.
Who makes intraocular injections of bevacizumab?
intraocular injections of bevacizumab is developed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).
Is intraocular injections of bevacizumab also known as anything else?
intraocular injections of bevacizumab is also known as glaucoma filtering surgery.
What development phase is intraocular injections of bevacizumab in?
intraocular injections of bevacizumab is in Phase 2.
Related
- Manufacturer: Samsung Medical Center — full pipeline
- Also known as: glaucoma filtering surgery
- Compare: intraocular injections of bevacizumab vs similar drugs
- Pricing: intraocular injections of bevacizumab cost, discount & access